228 related articles for article (PubMed ID: 17337182)
41. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
Jacobsohn K; Wang R
Asian J Androl; 2007 Jan; 9(1):3-7. PubMed ID: 17187154
[TBL] [Abstract][Full Text] [Related]
42. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
Shin HJ; Kim HJ; Kwak JH; Chun HO; Kim JH; Park H; Kim DH; Lee YS
Bioorg Med Chem Lett; 2002 Sep; 12(17):2313-6. PubMed ID: 12161123
[TBL] [Abstract][Full Text] [Related]
43. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
44. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
Beghyn T; Hounsou C; Deprez BP
Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
[TBL] [Abstract][Full Text] [Related]
45. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
Matic H; McCabe MP
Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
[TBL] [Abstract][Full Text] [Related]
46. FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A).
Lines TC; Ono M
Phytomedicine; 2006 Mar; 13(4):236-9. PubMed ID: 16492525
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors.
Jiang W; Alford VC; Qiu Y; Bhattacharjee S; John TM; Haynes-Johnson D; Kraft PJ; Lundeen SG; Sui Z
Bioorg Med Chem; 2004 Mar; 12(6):1505-15. PubMed ID: 15018924
[TBL] [Abstract][Full Text] [Related]
48. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
[No Abstract] [Full Text] [Related]
49. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.
Cellek S; Rees RW; Kalsi J
Expert Opin Investig Drugs; 2002 Nov; 11(11):1563-73. PubMed ID: 12437503
[TBL] [Abstract][Full Text] [Related]
50. A chemometric study of phosphodiesterase 5 inhibitors.
de O Figueiredo LJ; Garrido FM; Kunisawa VY; Aboim CE; Licks OB
J Mol Graph Model; 2006 Jan; 24(4):227-32. PubMed ID: 16185904
[TBL] [Abstract][Full Text] [Related]
51. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
Corbin JD; Beasley A; Blount MA; Francis SH
Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.
Dumaître B; Dodic N
J Med Chem; 1996 Apr; 39(8):1635-44. PubMed ID: 8648603
[TBL] [Abstract][Full Text] [Related]
53. Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Tsertsvadze A
Am J Ophthalmol; 2009 Oct; 148(4):625; author reply 625-6. PubMed ID: 19782802
[No Abstract] [Full Text] [Related]
54. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.
Sui Z; Guan J; Macielag MJ; Jiang W; Qiu Y; Kraft P; Bhattacharjee S; John TM; Craig E; Haynes-Johnson D; Clancy J
Bioorg Med Chem Lett; 2003 Feb; 13(4):761-5. PubMed ID: 12639576
[TBL] [Abstract][Full Text] [Related]
56. [How I treat and manage erectile dysfunction in diabetics].
Buvat J
Journ Annu Diabetol Hotel Dieu; 2006; ():185-203. PubMed ID: 17051861
[No Abstract] [Full Text] [Related]
57. PDE5 inhibition and fibrosis.
Corbin J
Int J Impot Res; 2005; 17(6):546. PubMed ID: 16258527
[TBL] [Abstract][Full Text] [Related]
58. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
Lee AG; Newman NJ
Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
[No Abstract] [Full Text] [Related]
59. Inhibition of cGMP-phosphodiesterase-5 by biflavones of Ginkgo biloba.
Dell'Agli M; Galli GV; Bosisio E
Planta Med; 2006 Apr; 72(5):468-70. PubMed ID: 16557462
[TBL] [Abstract][Full Text] [Related]
60. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
Pickard R
Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
